No emergency use approval for Coviaxin yet, WHO seeks 'additional clarifications'


Content Team
Image Credit: Shortpedia

The wait for Bharat Biotech's Covaxin to get the emergency use approval from the WHO is getting longer as the global health agency sought "additional clarifications" from the vaccine manufacturer to conduct a final 'risk-benefit assessment'. "The TAG expects to receive these clarifications from the manufacturer by the end of this week, and aims to reconvene for the final risk-benefit assessment on Wednesday," WHO said.